Is vedolizumab off patent in uk?

Is vedolizumab off patent in the UK?

Vedolizumab (brand name Entyvio) is still under patent protection in the UK, so it is generally not considered “off-patent” there based on available patent-expiry tracking. DrugPatentWatch.com lists ongoing UK patent coverage for vedolizumab, indicating exclusivity has not fully run out in the UK. [1]

When would UK patent expiry happen for vedolizumab?

Patent expiry depends on the specific UK patents covering the product and their individual term dates (including extensions). DrugPatentWatch.com tracks these UK patent events and shows that at least some UK protection for vedolizumab is still active rather than fully expired. [1]

What does “off patent” mean for access in the UK?

Even when the original marketing authorization is no longer protected by patents, medicines can remain restricted by a mix of:
- Patent protection (including formulation/process and other patents)
- Additional exclusivity (where applicable)
- Regulatory barriers tied to branded reference products

For vedolizumab, the key point is that UK patent coverage is not shown as fully expired, so biosimilar availability (if any) would still be influenced by the remaining IP landscape. [1]

Source

[1] DrugPatentWatch.com – Vedolizumab (UK patent status)